3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Lung Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Trauma, Nervous System
1
Thoracic Injuries
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Radiculopathy
1
Pneumonia
1
Pathologic Complete Response
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Laryngeal Neoplasms
1
Klippel-Feil Syndrome
1
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
Observation
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled